Delivery Order SPE2DB22D3016-SPE2DB25FBFY5
- Not listed
- The Defense Logistics Agency awarded a $1,353.24 delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 100GM under a firm fixed-price contract. This non-set-aside delivery order was issued on September 4, 2025, with an ultimate completion date of September 5, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a relatively small transaction within the broader federal pharmaceutical supply chain that the company...
- The Defense Logistics Agency awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This competitive, non-set-aside contract award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract operates under a firm fixed-price delivery order structure,...
- The Defense Logistics Agency awarded a delivery order valued at $25,629.43 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam 100GM on September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to the pharmaceutical distributor. The products will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Clindamycin Phosphate 1% Foam (100 grams) with a ceiling value of $1,553.04. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $1,744.22. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by October 23, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $9,741.64 under a firm fixed price contract. The award was made on August 26, 2025, with an ultimate completion date of August 27, 2025, and represents a non-set-aside, competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $3,700.26 under a firm fixed price contract. This non-set-aside delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units, with a ceiling value of $11,750.50. This is a firm fixed-price delivery order with no set-aside designation, indicating the contract was competitively awarded. The ultimate completion date is September 8, 2025, and the product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Clindamycin Phosphate 1% Foam in 100-gram units, with a ceiling value of $1,208.38. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,538.10 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This non-set-aside, competitively awarded delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilizes firm fixed price pricing and represents a...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBFY5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,309.22 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam in 50-gram units. This competitively awarded, firm fixed-price delivery order was issued on August 22, 2025, with an ultimate completion date of August 25, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. As a prime vendor for the DLA's global pharmaceutical supply chain, AmerisourceBergen provides comprehensive medical commodities to support military healthcare programs, including specialty medications, generic and brand-name drugs, vaccines, and related medical supplies. The company's federal contract portfolio demonstrates consistent capability to fulfill competitive procurement requirements across multiple therapeutic domains for defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/22/25 |